Comparative Pharmacology
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER versus TRASICOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER versus TRASICOR.
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER vs TRASICOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist with no intrinsic sympathomimetic activity or membrane stabilizing activity. Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors predominantly in cardiac tissue.
Non-selective beta-adrenergic antagonist with intrinsic sympathomimetic activity (partial agonist) at beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min IV for 4 minutes. Titrate by 50 mcg/kg/min increments every 4 minutes as needed to maximum of 200 mcg/kg/min. For double-strength (20 mg/mL) formulation, adjust infusion rate accordingly.
20-40 mg orally three times daily, increased to 80-160 mg daily if needed; maximum 320 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes. Clinical context: ultra-short acting beta-blocker, steady state achieved within 30 minutes.
Terminal elimination half-life is approximately 8-12 hours in patients with normal renal function; may be prolonged in renal impairment, requiring dose adjustment.
Rapid metabolism by red blood cell esterases; metabolites are inactive. Less than 2% excreted unchanged in urine.
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of elimination, with about 20% appearing as unchanged drug; biliary/fecal excretion accounts for the remaining 20%.
Category A/B
Category C
Beta-Blocker
Beta-Blocker